VBLT
Vascular Biogenics Ltd
Price:  
0.16 
USD
Volume:  
5,652,730.00
Israel | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

VBLT WACC - Weighted Average Cost of Capital

The WACC of Vascular Biogenics Ltd (VBLT) is 7.0%.

The Cost of Equity of Vascular Biogenics Ltd (VBLT) is 10.40%.
The Cost of Debt of Vascular Biogenics Ltd (VBLT) is 5.00%.

Range Selected
Cost of equity 8.70% - 12.10% 10.40%
Tax rate 26.20% - 27.00% 26.60%
Cost of debt 5.00% - 5.00% 5.00%
WACC 6.2% - 7.9% 7.0%
WACC

VBLT WACC calculation

Category Low High
Long-term bond rate 4.2% 4.7%
Equity market risk premium 5.0% 6.0%
Adjusted beta 0.9 1.16
Additional risk adjustments 0.0% 0.5%
Cost of equity 8.70% 12.10%
Tax rate 26.20% 27.00%
Debt/Equity ratio 1 1
Cost of debt 5.00% 5.00%
After-tax WACC 6.2% 7.9%
Selected WACC 7.0%

VBLT's CAPM model and how its cost of Equity is calculated

The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.

This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.

Here’s how we figure out the cost of equity for VBLT:

cost_of_equity (10.40%) = risk_free_rate (4.45%) + equity_risk_premium (5.50%) * adjusted_beta (0.9) + risk_adjustments (0.25%)

We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.